The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Lenalidomide and rituximab combination for R/R PCNSL-DLBCL patients

Feb 15, 2019

Herve Ghesquieresfrom Hospices Civil de Lyonand University Claude Bernard Lyon 1, along with colleagues, recently published in Annals of Oncology the results of a phase II trial investigating the efficacy of lenalidomide in combination with rituximab in relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL) patients.

In this open-label, multicenter, singe-arm, prospective, phase II trial the efficacy of intravenous rituximab together with lenalidomide (R 2) was assessed in diffuse large B-cell lymphoma (DLBCL)-PCNSL patients and in primary intraocular lymphoma patients. The primary endpoint of this study was overall response rate (ORR). Secondary endpoints included, progression-free survival (PFS), overall survival (OS), and safety.  

Study design & baseline characteristics

  • N = 45 R/R DLBCL patients with either:
    • Brain involvement: n = 34; and/or
    • cerebrospinal fluid (CSF) involvement: n = 11
  • Dosing:
    • Induction phase: eight 28-day cycles of R 2
      • Lenalidomide: 20 mg orally daily during cycle 1 (Day 1−21) and thereafter 25 mg daily
      • Rituximab: 375 mg/m 2intravenously (IV) on Day 1
    • Maintenance phase: initiated only in patients responding to induction phase
      • Lenalidomide: 10 mg daily from Day 1−21 for a maximum of twelve 28-day cycles
    • Corticosteroids were allowed during induction cycle 1 for patients with symptomatic brain edema:
      • Twenty-nine patients required corticosteroids during cycle 1
    • Intrathecal methotrexate (MTX) was allowed for patients with CSF lymphoma involvement:
      • Seven patients with CNS involvement received MTX
    • Median patients age (range): 69 (48−86) years
    • All patients had DLBCL diagnosis with CNS involvement

Key findings

  • Median number of R 2cycles (range): 7 (1−8)
  • Treatment discontinuation during the induction phase occurred in 60% (n = 27) of patients, due to:
    • Progressive disease (PD): n = 23 patients
    • Treatment-related toxicity: n= 2 patients
    • Consent withdrawal: n = 2 patients
  • ORR at the end of the induction phase (n = 45): 35.6% (95% CI, 21.9−51.2%)
  • ORR at the end of the induction phase in the intention-to-treat (ITT) population (n = 50): 32.0% (95% CI, 21.9-51.2)
  • Patients completing induction phase (eight R 2cycles): 51% of patients (n = 23)
  • Patients maintaining an objective response over six months: n = 8 patients
  • Patients maintaining an objective response over 12 months: n = 3 patients
  • Patients maintaining an objective response over 18 months: n = 1 patient
  • Among the patients with brain localization (n = 34):
    • ORR: 64.7% (95% CI, 46.5−3%)
    • Complete response (CR): 35% (n = 12)
    • Partial response (PR): 29% (n = 10)
  • Patients starting maintenance treatment: n = 18 (12 CR, 3 PR, and 3 PD/stable disease [SD])
  • Median cycles of maintenance treatment (range): 5 (1−12)
  • Patients completing 12 cycles of maintenance treatment: n = 5, of those:
    • PD: n = 1
    • Remained in CR: n = 4
  • At the last follow-up:
    • Two patients remain in CR and two relapsed at 3.8 and 6.5 months after the end of the maintenance phase
  • At a median follow-up of 19.2 months (range, 1.5−31):
    • Median PFS: 7.8 months (95% CI, 3.9−11.3)
    • Median OS: 17.7 months (95% CI, 12.9−not reached)
    • Median time to best response (range): 1.2 months (0.3−7.6)
  • For responding patients:
    • Median PFS: 9.2 months
  • For patients with brain localization (n = 34):
    • Median PFS: 3.9 months
  • Patients who responded to treatment showed a higher CD4/CD8 ratio at baseline and a continuous increase in this ratio during treatment
  • A CD4/CD8 ratio of 1.6 was able to discriminate between prolonged and short PFS patient populations ( P= 0.03)

Safety

  • Twenty patients (44%) had Grade 3−4 neutropenia
  • Three patients presented with Grade 3 pneumonitis and one patient with Grade 3 Clostridium difficilecolitis after cycle 1 and orchiepididymitis after cycle 2
  • During the induction phase the most common adverse events (AEs) reported were:
    • Grade 3 asthenia: 13% (n = 6 patients)
    • Paresthesia: 4% (n = 2 patients)
    • Grade 3 rash: 2% (n = 1 patient)
    • Melanoma: n = 1 patient
  • Serious AEs (n = 19) were reported in 33% of patients (n = 15)
  • Lenalidomide dose reduction occurred in n = 19 patients, mainly due to haematological toxicity  

Conclusions

R 2in R/R DLBCL-PCNSL patients showed promising activity. Nevertheless, further studies are needed to validate these results as the possibility that R 2together with MTX-based chemotherapy might present a good first-line regimen for PCNSL.

  1. Ghesquieres H. et al.Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Relapsed/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: a Multicenter Prospective "Proof of Concept" Phase II Study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol . 2019 Jan 29. DOI: 10.1093/annonc/mdz032[Epub ahead of print].